Bristol-Myers Squibb, Simcere partner to develop cardiovascular compound

Wednesday, December 14, 2011

Bristol-Myers Squibb and Simcere Pharmaceutical Group have expanded the strategic partnership formed last year to include a second collaboration in a different therapeutic area. The companies agreed to co-develop BMS-795311, Bristol-Myers Squibb’s preclinical small molecule inhibitor of the Cholesteryl Ester Transfer Protein (CETP).  Inhibiting CETP could potentially raise HDL levels and help prevent cardiovascular disease.

[Read More]

Apexigen/Simcere file for IND in China

Thursday, March 17, 2011

Apexigen, a biopharmaceutical company focusing on the development of monoclonal antibody therapeutics, said its partner, Simcere Pharmaceutical Group of China, filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) of China to evaluate APX003 (also known as BD0801) as a potential cancer therapy, according to Fierce Biotech.

[Read More]